Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for relieving glucocorticoid side effects

A technology for glucocorticoids and side effects, which is applied in the field of alleviating the side effects of glucocorticoids, and can solve problems such as increased upper gastrointestinal bleeding or perforation

Inactive Publication Date: 2018-12-21
GUANGDONG MEDICAL UNIV
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Oral glucocorticoid therapy approximately doubles the risk of upper gastrointestinal bleeding or perforation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for relieving glucocorticoid side effects
  • Method for relieving glucocorticoid side effects
  • Method for relieving glucocorticoid side effects

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] Example 1 The effect of the compound of formula I of the present invention on osteogenesis-related genes in the inhibition of MC3T3-E1 cell osteogenic differentiation by dexamethasone

[0039] MC3T3-E1 cells were cultured in groups

[0040] (1) After the cells were cultured to a confluence of 80%, the cells were digested, and the digested cells were prepared into a uniform single-cell suspension with α-MEM complete medium, and the cell density was adjusted to 10 5 cells / well; take a 6-well plate, inoculate 2ml of cell suspension in each well, and culture in a carbon dioxide incubator.

[0041] (2) Grouping treatment: 24 hours after seeding the plate, the cells grew to reach a confluence of 80% to 90%, and the cells were divided into groups, 3 wells / group, and the corresponding medium was replaced every other day, 2ml / well. Grouped as follows:

[0042] ① OM induction medium α-MEM culture treatment group (OM induction medium composition: 10mM β-sodium glycerophosphate, ...

Embodiment 2

[0057] Example 2 The effect of the compound of formula I of the present invention on the expression of osteogenesis-related proteins and the JNK signaling pathway in inhibiting the osteogenic differentiation of MC3T3-E1 cells.

[0058] (1) Cell grouping: 24 hours after seeding the plate, the cell growth reached 80%-90% confluence, and the cells were grouped into 3 wells / group, and 2 ml / well of the corresponding medium was replaced every other day. Grouped as follows:

[0059] ① OM induction medium α-MEM culture treatment group

[0060] ②10 -6 M Dex+OM induction medium α-MEM culture treatment group

[0061] ③10μM compound of formula I of the present invention+10 -6 M Dex+OM induction medium α-MEM culture treatment group

[0062] ④ 20μM compound of formula I of the present invention+10 -6 M Dex+OM induction medium α-MEM culture treatment group

[0063] (2) Cell total protein was extracted on the 5th day of cell group culture.

[0064] (3) Determination of protein concentr...

Embodiment 3

[0069] Example 3 The protective effect of the compound of formula I of the present invention on the reduction of mineralization formation of MC3T3-E1 cells inhibited by dexamethasone.

[0070] (1) Cell inoculation and culture: the digested cells were prepared into a uniform single-cell suspension with α-MEM complete medium, and the cell density was adjusted to 2.5×10 4 cells / well; take a 24-well plate, inoculate 500 μl of cell suspension in each well, and culture in a carbon dioxide incubator.

[0071] (2) Cell grouping treatment: 24 hours after cell seeding, the cells grew to reach 80%-90% confluence, and the cells were grouped into 4 wells / group, and the corresponding medium was replaced every other day, 500 μl / well. Grouped as follows:

[0072] ① OM induction medium α-MEM culture treatment group

[0073] ②10 -6 M Dex+OM induction medium α-MEM culture treatment group

[0074] ③10μM compound of formula I of the invention+10 -6 M Dex+OM induction medium α-MEM culture trea...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of a natural compound in relieving glucocorticoid side effects.

Description

technical field [0001] The invention relates to the application of a natural compound in alleviating the side effects of glucocorticoids. Background technique [0002] Since P.Hench, E.Kendall and T.Reichstein first reported the use of glucocorticoids in the journal Annals of the rheumatic diseases for the treatment of rheumatoid arthritis in 1949, glucocorticoids have been known for their excellent anti-inflammatory activity and Immunosuppression is widely used clinically in inflammation, autoimmune diseases and organ transplantation. It has been reported that about 1% of the population in the United States is receiving long-term treatment with glucocorticoids, and the proportion of oral glucocorticoids in the community is between 0.5% and 0.9% (65% of whom are women). The proportion is as high as 2.7% in women aged ≥50 years; in the female osteoporosis study covering 10 countries, about 4.6% of the 60,393 postmenopausal women who were followed up daily were receiving gluc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P3/04A61P25/24A61P3/10A61P3/06A61P9/00A61P19/00A61P19/10A61P27/12A61P25/00
CPCA61K31/352A61P3/04A61P3/06A61P3/10A61P9/00A61P19/00A61P19/10A61P25/00A61P25/24A61P27/12
Inventor 徐道华王清辉周晨慧谢保城吴佳欢
Owner GUANGDONG MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com